MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3851/imp3372

Медицинская библиотека · Antiviral therapy · 2020

Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

Jia Jidong, Shang Jia, Tang Hong, Jiang Jiaji, Ning Qin, Dou Xiaoguang, Zhang Shuqin, Zhang Mingxiang, Han Tao, Tan Deming, Zhou Xinmin, Chen Guoliang, Sheng Jifang, Su Zhijun, Chen Haijun, Dai Erhei, Ye Yinong, Guo Ying, Shen Yuefei, Yuan Jing, Wei Zhen, Zhu Siyun, EVOLVE Study Group

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

In China, the optimal management of individuals living with chronic HBV infection (CHB) remains an unmet need. The EVOLVE Study was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naive CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies.

METHODS

Males or females aged ≥18 years, diagnosed with CHB regardless of cirrhosis or hepatitis B e antigen (HBeAg) status were enrolled from tier 2 city hospitals (between 2012-2014). The choice of initial therapy and subsequent treatment modifications was at the discretion of treating physicians. Key outcomes included treatment modifications, virological response (HBV DNA <300 copies/ml) and HBV disease progression.

RESULTS

Of the 3,408 patients enrolled, 1,807 and 628 received ETV and LAM-based therapy, respectively. The mean age was 39.5 years, 74% were male and 22.9% had cirrhosis. The rate of treatment modification was higher in the LAM-based versus ETV group (25.9% versus 13.7%); viral breakthrough was the most common reason in the LAM-based group versus financial reasons in the ETV group. At week 240, the virological response rate was 73% in both treatment groups. Compared with LAM-based therapy, ETV was associated with a significantly lower incidence of viral breakthrough (12.6% versus 2.1%) and genotypic resistance (10.1% versus 1.2%; P<0.0001 for both); significantly lower risk of HBV disease progression (14.0% versus 10.7%; P=0.0113); and lower rates of progression to decompensated cirrhosis (9.6% versus 6.4%) and hepatocellular carcinoma (1.9% versus 0.8%).

CONCLUSIONS

This real-world, longitudinal study demonstrated a significantly lower risk of HBV-related disease progression, viral breakthrough and resistance with ETV versus LAM-based therapy. ClinicalTrials.gov NCT01726439.

Для цитирования: Jia Jidong, Shang Jia, Tang Hong, Jiang Jiaji, Ning Qin, Dou Xiaoguang, Zhang Shuqin, Zhang Mingxiang, Han Tao, Tan Deming, Zhou Xinmin, Chen Guoliang, Sheng Jifang, Su Zhijun, Chen Haijun, Dai Erhei, Ye Yinong, Guo Ying, Shen Yuefei, Yuan Jing, Wei Zhen, Zhu Siyun, EVOLVE Study Group. Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.. Antiviral therapy. 2020. DOI: 10.3851/imp3372.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.